Drug Profile
AZD 1386
Alternative Names: AZD-1386Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Analgesics
- Mechanism of Action TRPV cation channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gastro-oesophageal reflux; Musculoskeletal pain; Pain
Most Recent Events
- 27 Jan 2011 Discontinued - Phase-II for Gastro-oesophageal reflux in Denmark (PO)
- 27 Jan 2011 Discontinued - Phase-II for Gastro-oesophageal reflux in Sweden (PO)
- 29 Jul 2008 AstraZeneca initiates enrolment in a phase I trial examining oesophageal hypersensitivity in healthy subjects in Denmark